RxDoctor Payments Data

Jitendra Swarup, MD

Ophthalmology · Elizabeth City, NCNPI 1467490854

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 200 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by Alcon at 32.7% of the total.

$4,887in general payments, 2019–2025

Across 200 payments — averaging $24.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$2K
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$918
  • Ocular Therapeutix, Inc.$503
  • Glaukos Corporation$330
  • Harrow Eye, LLC$283
  • Johnson & Johnson Surgical Vision, Inc.$181
  • plus $1K from 17 others
$446,272in research payments, 2019–2025

Across 210 payments — averaging $2125.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Glaukos Corporation$251K
  • AbbVie$153K
  • Johnson & Johnson Surgical Vision, Inc.$32K
  • Alcon Research LLC$10K

What the payments were for

  • Food & beverage$4,887100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,887 in reported general payments places this provider in the 80th percentile of 588 ophthalmology providers in North Carolina.

See all ophthalmology providers in North Carolina

Medicare billing

Part B allowed, 2024
$955,987
Medicare patients
1,102
Services billed
6,241

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate264$14,891
Ketorolac Tromethamine290$9,524
Ciprofloxacin Hcl248$3,004
ErythromycinErythromycin Base32$319
Latanoprost32$285
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat12$192
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha17$178
Tobramycin13$78
Azithromycin22$45
Diazepam22$11

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Elizabeth City

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →